• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

修订后的献血前指导方针未能阻止有高危行为史的人献血。

Failure of the revised pre-donation guidelines to prevent people with a history of high-risk behaviour from donating blood.

作者信息

Neal K R, Jones D A, James V

机构信息

Department of Public Health Medicine and Epidemiology, University of Nottingham, U.K.

出版信息

Transfus Med. 1994 Sep;4(3):227-9. doi: 10.1111/j.1365-3148.1994.tb00276.x.

DOI:10.1111/j.1365-3148.1994.tb00276.x
PMID:7820231
Abstract

We have evaluated the effectiveness of the alteration in the literature aimed at the self-exclusion of blood donors with a history of high-risk behaviour. Since the introduction of anti-HCV screening on 1 September 1991 all HCV-positive donors in the Trent Region have been invited for interview by Blood Transfusion medical staff to ascertain risk factors for HCV infection. We have compared the 5-month periods before (1 September, 1992 to 31 January, 1993) and after (1 February, 1993 to 30 June, 1993) the introduction of the amended literature on 1 February, 1993. No differences between the two time periods were noted for the prevalence rate of HCV infection amongst new or repeat donors, or history of risk factors or specific exclusion criteria. The new literature is failing to exclude people with a history of high-risk behaviour from donating blood and further study of this problem is urgently required.

摘要

我们评估了文献中针对有高危行为史的献血者进行自我排除的相关改变的有效性。自1991年9月1日引入抗丙型肝炎病毒(HCV)筛查以来,特伦特地区所有HCV阳性献血者均被输血医务人员邀请进行访谈,以确定HCV感染的风险因素。我们比较了1993年2月1日引入修订文献之前(1992年9月1日至1993年1月31日)和之后(1993年2月1日至1993年6月30日)这两个5个月期间。在新献血者或重复献血者中,HCV感染的患病率、风险因素史或特定排除标准方面,两个时间段之间未发现差异。新文献未能将有高危行为史的人排除在献血之外,因此迫切需要对这一问题进行进一步研究。

相似文献

1
Failure of the revised pre-donation guidelines to prevent people with a history of high-risk behaviour from donating blood.修订后的献血前指导方针未能阻止有高危行为史的人献血。
Transfus Med. 1994 Sep;4(3):227-9. doi: 10.1111/j.1365-3148.1994.tb00276.x.
2
[Risk behavior among blood donors: efficacy of a new questionnaire].[献血者中的风险行为:一份新问卷的有效性]
Transfus Clin Biol. 1999 Jul;6(4):227-35. doi: 10.1016/s1246-7820(99)80033-0.
3
Successful exclusion of blood-borne viral disease in blood donors.成功排除献血者的血源性病原体。
Eur J Intern Med. 2011 Dec;22(6):e71-4. doi: 10.1016/j.ejim.2011.07.002. Epub 2011 Jul 27.
4
Understanding non-disclosure of deferrable risk: a study of blood donors with a history of intravenous drug use.理解可延缓风险的未披露情况:一项针对有静脉吸毒史献血者的研究。
Transfus Med. 2010 Feb;20(1):15-21. doi: 10.1111/j.1365-3148.2009.00969.x. Epub 2009 Sep 30.
5
Hepatitis C seroprevalence in accepted versus deferred blood-donor candidates evaluated by medical history and self-exclusion form.通过病史和自我排除表格评估的合格与延期献血者候选人中的丙型肝炎血清流行率。
Transfusion. 2004 Sep;44(9):1344-9. doi: 10.1111/j.1537-2995.2004.03379.x.
6
Risk factors for hepatitis C virus infection among blood donors in northern Thailand.泰国北部献血者中丙型肝炎病毒感染的危险因素。
Transfusion. 2004 Oct;44(10):1433-40. doi: 10.1111/j.1537-2995.2004.04073.x.
7
[Infection risk and efficacy of clinical selection techniques for volunteer blood donors].[无偿献血者临床筛选技术的感染风险与效果]
Transfus Clin Biol. 1997 Dec;4(6):513-21. doi: 10.1016/s1246-7820(97)80076-6.
8
Hepatitis C virus: routes of infection and genotypes in a cohort of anti-HCV-positive French blood donors.丙型肝炎病毒:一组抗-HCV阳性法国献血者的感染途径和基因型
Vox Sang. 2000;79(3):138-44. doi: 10.1159/000031231.
9
Risk factors for hepatitis B and C infection among blood donors in five Chinese blood centers.中国五个血液中心献血者中乙型和丙型肝炎感染的危险因素。
Transfusion. 2015 Feb;55(2):388-94. doi: 10.1111/trf.12850. Epub 2014 Nov 10.
10
Hepatitis C seroprevalence amongst injecting drug users attending a methadone programme.参与美沙酮项目的注射吸毒者中丙型肝炎血清流行率。
N Z Med J. 1995 Sep 8;108(1007):364-6.